Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent Technologies (NYSE: A) reported strong Q3 2025 financial results with revenue of $1.74 billion, representing 10.1% reported growth and 6.1% core growth year-over-year. The company achieved GAAP EPS of $1.18 (up 22%) and non-GAAP EPS of $1.37 (up 4%).
All three business segments showed growth: Life Sciences and Diagnostics Markets Group revenue increased 14% to $670 million, Agilent CrossLab Group grew 8% to $744 million, and Applied Markets Group rose 7% to $324 million.
Agilent raised its full-year 2025 outlook, projecting revenue between $6.91-6.93 billion (6.2-6.5% growth) and non-GAAP EPS of $5.56-5.59. Q4 2025 revenue is expected at $1.822-1.842 billion with non-GAAP EPS of $1.57-1.60.
Helzberg, a subsidiary of Berkshire Hathaway (NYSE:BRK), has announced a national partnership with Big Brothers Big Sisters of America (BBBSA) ahead of Big Brothers Big Sisters Month in September 2025. The collaboration combines financial investment, volunteer engagement, and career exploration opportunities to enhance youth mentorship nationwide.
The partnership launched in Kansas City with BBBSA's Diamond Anniversary celebration at Kauffman Stadium and will continue with various events including a special gathering at the KC Current match on August 30. Helzberg's nationwide network of associates will participate in volunteer efforts including career day mentoring and Pack + Give Back events across key markets.
Agilent Technologies (NYSE: A) announced that President and CEO Padraig McDonnell will participate in a fireside chat at the Wells Fargo Healthcare Conference. The presentation is scheduled for September 3, 2025, from 11:00 to 11:35 AM ET in Everett, Massachusetts. Investors can access both the live audio webcast and replay through Agilent's Investor Relations website.
Agilent Technologies (NYSE: A) has received FDA approval for its MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic test for colorectal cancer. The test identifies mismatch repair deficient (dMMR) colorectal cancer patients eligible for treatment with Bristol Myers Squibb's Opdivo alone or in combination with Yervoy.
The panel is the only FDA-approved companion diagnostic IHC panel for this specific purpose and is exclusively designed for use with Agilent's Dako Omnis automated staining solution. The test detects loss of function in four key MMR proteins (MLH1, PMS2, MSH2, and MSH6) in colorectal cancer tissue, helping identify patients who may respond better to immunotherapy.
TORM plc (NASDAQ: TRMD) reported Q2 2025 financial results with TCE earnings of USD 208.2 million and a net profit of USD 58.7 million, showing a year-over-year decline from Q2 2024's exceptional performance. The company achieved average TCE rates of USD 26,672 per day across its fleet.
TORM declared a quarterly dividend of USD 0.40 per share, representing a 67% payout ratio. The company has also secured financing commitments of up to USD 857 million to refinance existing loans and lease agreements.
Following strong performance and positive outlook, TORM has raised its full-year 2025 guidance, projecting TCE earnings of USD 800-950 million and EBITDA of USD 475-625 million.
Agilent Technologies (NYSE:A) and Georgia Tech have announced the establishment of an Agilent Center of Excellence (CoE) for Environmental Health and Engineering. The center will be led by renowned environmental scientist Professor Shane Snyder from Georgia Tech's School of Civil and Environmental Engineering.
The CoE will focus on advancing research in environmental sustainability, water recycling, and biologics. Key research areas include developing novel water recycling technologies, waste material upcycling, and cell-based analysis of environmental mixtures. This marks Agilent's third CoE in the U.S. and will be uniquely positioned to evaluate environmental contaminants and toxicity.
Agilent Technologies (NYSE: A) has launched three new models in its Dako Omnis instrument family to address diverse pathology laboratory needs. The new lineup includes the Dako Omnis 110 for low-medium volume labs (110 IHC slides/day), Dako Omnis 165 for medium-high volume labs (165 IHC slides/day), and Dako Omnis 165 Duo for simultaneous IHC and ISH processing.
The new instruments feature continuous case-based processing, shared reagents, and an integrated direct connection for de-ionized water and non-hazardous waste to improve workflow efficiency. The products will be initially available in the U.S., Europe, and Australia, with debuts planned at the European Congress of Pathology and National Society for Histotechnology events.
Crawford & Company (NYSE: CRD-A and CRD-B) announced an increase in its quarterly dividend. The Board of Directors approved a quarterly dividend of $0.075 per share for both Class A and Class B Common Stock, representing a $0.005 increase from the previous quarter.
The dividend will be paid on August 29, 2025, to shareholders of record as of August 15, 2025.
Agilent Technologies (NYSE: A) has announced it will release its third quarter fiscal 2025 financial results on Wednesday, August 27, 2025, after market close. The company will host a conference call at 1:30 p.m. PDT the same day to discuss the results. Investors can access the listen-only webcast through the Events section of Agilent's investor relations website. A replay of the call will remain available on the website for 90 days.
Agilent Technologies (NYSE: A) announced that Senior Vice President and CFO Bob McMahon will step down effective July 31, as he relocates to the East Coast for family reasons. Rodney Gonsalves, the company's current corporate controller and principal accounting officer, will serve as interim CFO while a global search for McMahon's successor is conducted.
The company also confirmed that its Q3 FY2025 financial results, to be released on August 27, are expected to be within the previously provided guidance range. Agilent maintains confidence in its long-term plans.